BrightPath BiotherapeuticsBrightPath Biotherapeutics Co., Ltd.4594東証グロース医薬品FY ending Mar 2025, non-consolidated, J-GAAP

What does BrightPath Biotherapeutics do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

※ Operating cash flow is negative

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income-¥1.15B

Operating cash flow-¥1.25B

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow-¥1.25B

Free cash flow-¥1.25B

Net income-¥1.15B

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第23期(2025/04/01－2026/03/31)
ID S100YJ3C2026-06-25Open
EDINET (FSA Japan)
有価証券報告書－第22期(2024/04/01－2025/03/31)
ID S100VZBU2025-06-19Open
EDINET (FSA Japan)
有価証券報告書－第21期(2023/04/01－2024/03/31)
ID S100TP5I2024-06-21Open
EDINET (FSA Japan)
有価証券報告書－第20期(2022/04/01－2023/03/31)
ID S100QKJ22023-06-22Open
EDINET (FSA Japan)
訂正有価証券報告書－第19期(令和3年4月1日－令和4年3月31日)
ID S100PTK62022-12-19Open
EDINET (FSA Japan)
有価証券報告書－第18期(令和2年4月1日－令和3年3月31日)
ID S100LQ6N2021-06-25Open

Extracted from XBRL: 40 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.